Drug Type Degradable Molecular Glue |
Synonyms E7820, ER-68203-00, ER-6820300 + [1] |
Target |
Action degraders |
Mechanism CD49b degraders(integrin subunit alpha 2 degraders), RBM39 degraders(RNA binding motif protein 39 degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H12N4O2S |
InChIKeyLWGUASZLXHYWIV-UHFFFAOYSA-N |
CAS Registry289483-69-8 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Myelomonocytic Leukemia | Phase 2 | United States | 13 Aug 2021 | |
| Myeloid Tumor | Phase 2 | United States | 13 Aug 2021 | |
| Refractory acute myeloid leukemia | Phase 2 | United States | 13 Aug 2021 | |
| Refractory Myelodysplastic Syndrome | Phase 2 | United States | 13 Aug 2021 | |
| Colonic Cancer | Phase 2 | United States | 30 Sep 2011 | |
| Colonic Cancer | Phase 2 | Argentina | 30 Sep 2011 | |
| Colonic Cancer | Phase 2 | Australia | 30 Sep 2011 | |
| Colonic Cancer | Phase 2 | Brazil | 30 Sep 2011 | |
| Colonic Cancer | Phase 2 | Russia | 30 Sep 2011 | |
| Colonic Cancer | Phase 2 | Ukraine | 30 Sep 2011 |
Phase 1/2 | 5 | FOLFIRI+E7820 | pddhnqqtqq = nkmidxivar wsveqzdvko (ytpsofbnek, zvtbqwbctw - zdtagqietp) View more | - | 07 Nov 2023 | ||
Phase 1/2 | 82 | (Phase 1b, All Participants) | jwkpwgizze = czlhqgabxk jnjyfytktc (kvorvrlwbe, qycjzbhhfg - htddksdisu) | - | 25 Nov 2022 | ||
(Phase 2: E7820 70 mg + Irinotecan) | hqrfejhhdi = fvvghifljv hqyhdxkiwu (wrmrkbxmzs, qehwviaouj - etckipuxha) View more | ||||||
Phase 2 | 12 | wylriehhnp(bkbpqygilu) = zfpuxeeqbb txbutxmsro (bnznwbulnt, 1.5 - NR) View more | Positive | 15 Nov 2022 | |||
Phase 1 | 45 | (Treatment Phase Part A: E7820 50 mg Fed) | jfqsoamrfx(gigrahxeha) = sjxnjooobz dwojuxrnev (oqtmgdhmti, 3510) View more | - | 18 Jan 2020 | ||
(Treatment Phase Part A: E7820 50 mg Fasted) | jfqsoamrfx(gigrahxeha) = okwtpmbuxv dwojuxrnev (oqtmgdhmti, 3490) View more | ||||||
Phase 2 | 28 | fgjeygyrcp(srxuepjlro) = E7820 related-grade 3 toxicities included increased AST (3/28, 11%), increased ALT (2/28, 7%), and diarrhea, hypomagnesemia, decreased glomerular filtration rate and elevated creatinine (1/28, 3% in each) qdpftpmccb (jissxatwbx ) View more | Negative | 20 May 2010 | |||
Phase 1 | 17 | yjcavtghyl(dqgjbtxkle) = ayuiockdmr dwnsctqgpl (yhpxlhjkst ) View more | - | 20 May 2008 | |||
Phase 1 | 30 | dffcyxtaie(qtdzlxongu) = ohecvzwizo gwuugswkpk (wojjpwcosv ) | - | 20 Jun 2006 |





